Genome Protection

Genome Protection, Inc. is a clinical-stage biopharmaceutical company focused on developing medical interventions to prevent and treat aging and age-related diseases. The Company's technologies are based on deep insights in the intrinsic mechanisms leading to genomic instability, impairment of immunity ("immunosenescence"), and systemic inflammatio... n ("inflammaging") in aging. Genome Protection develops drugs that counteract these mechanisms, including TLR5 agonists entolimod and GP532, that are projected to improve immune functions in the elderly. The Company is also applying its broad research and development capabilities to fuel a sustainable pipeline of innovative small-molecule and immunotherapeutic drug candidates that target intrinsic mechanisms underlying genomic instability in somatic tissues during aging and cancer progression and driven by the activity of endogenous retroelements ('retrobiome').Read More